Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma
Public ClinicalTrials.gov record NCT01771107. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This pilot phase I/II trial studies the side effects and the best dose of brentuximab vedotin when given together with combination chemotherapy and to see how well they work in treating patients with stage II-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a chemotherapy drug called vedotin. Brentuximab attaches to CD30-positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.
Study identification
- NCT ID
- NCT01771107
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 41 participants
Conditions and interventions
Conditions
- AIDS-Related Hodgkin Lymphoma
- Ann Arbor Stage II Hodgkin Lymphoma
- Ann Arbor Stage IIA Hodgkin Lymphoma
- Ann Arbor Stage IIB Hodgkin Lymphoma
- Ann Arbor Stage III Hodgkin Lymphoma
- Ann Arbor Stage IIIA Hodgkin Lymphoma
- Ann Arbor Stage IIIB Hodgkin Lymphoma
- Ann Arbor Stage IV Hodgkin Lymphoma
- Ann Arbor Stage IVA Hodgkin Lymphoma
- Ann Arbor Stage IVB Hodgkin Lymphoma
- Classic Hodgkin Lymphoma
- HIV Infection
Interventions
- Brentuximab Vedotin Drug
- Dacarbazine Drug
- Doxorubicin Hydrochloride Drug
- Pharmacological Study Other
- Vinblastine Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2013 (Actual)
- Primary completion
- Oct 15, 2021 (Actual)
- Completion
- Mar 21, 2024 (Actual)
- Last update posted
- Aug 15, 2025
2013 – 2024
United States locations
- U.S. sites
- 20
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| UCLA Center for Clinical AIDS Research and Education | Los Angeles | California | 90035 | — |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles | California | 90095 | — |
| University of California Davis Comprehensive Cancer Center | Sacramento | California | 95817 | — |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami | Florida | 33136 | — |
| John H Stroger Jr Hospital of Cook County | Chicago | Illinois | 60612 | — |
| Louisiana State University Health Science Center | New Orleans | Louisiana | 70112 | — |
| Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland | 21287 | — |
| Boston Medical Center | Boston | Massachusetts | 02118 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Siteman Cancer Center at Washington University | St Louis | Missouri | 63110 | — |
| Washington University - Jewish | St Louis | Missouri | 63110 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Montefiore Medical Center-Einstein Campus | The Bronx | New York | 10461 | — |
| Pennsylvania Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
| Harborview Medical Center | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01771107, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 15, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01771107 live on ClinicalTrials.gov.